Karacaer Zehra, Cakir Banu, Erdem Hakan, Ugurlu Kenan, Durmus Gul, Ince Nevin Koc, Ozturk Cinar, Hasbun Rodrigo, Batirel Ayse, Yilmaz Esmeray Mutlu, Bozkurt Ilkay, Sunbul Mustafa, Aynioglu Aynur, Atilla Aynur, Erbay Ayse, Inci Ayse, Kader Cigdem, Tigen Elif Tukenmez, Karaahmetoglu Gokhan, Coskuner Seher Ayten, Dik Ebru, Tarakci Huseyin, Tosun Selma, Korkmaz Fatime, Kolgelier Servet, Karadag Fatma Yilmaz, Erol Serpil, Turker Kamuran, Necan Ceyda, Sahin Ahmet Melih, Ergen Pinar, Iskender Gulsen, Korkmaz Pinar, Eroglu Esma Gulesen, Durdu Yasemin, Ulug Mehmet, Deniz Suna Secil, Koc Filiz, Alpat Saygın Nayman, Oztoprak Nefise, Evirgen Omer, Sozen Hamdi, Dogan Mustafa, Kaya Selcuk, Kaya Safak, Altindis Mustafa, Aslan Emel, Tekin Recep, Sezer Busra Ergut, Ozdemir Kevser, Ersoz Gulden, Sahin Ahmet, Celik Ilhami, Aydin Emsal, Bastug Aliye, Harman Rezan, Ozkaya Hacer Deniz, Parlak Emine, Yavuz Ilknur, Sacar Suzan, Comoglu Senol, Yenilmez Ercan, Sirmatel Fatma, Balkan Ilker Inanc, Alpay Yesim, Hatipoglu Mustafa, Denk Affan, Senol Gunes, Bitirgen Mehmet, Geyik Mehmet Faruk, Guner Rahmet, Kadanali Ayten, Karakas Ahmet, Namiduru Mustafa, Udurgucu Hatice, Boluktas Rukiye Pinar, Karagoz Ergenekon, Ormeci Necati
Department of Infectious Diseases and Clinical Microbiology, Etimesgut Military Hospital, Ankara, Turkey.
Institute of Public Health, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Health Qual Life Outcomes. 2016 Nov 3;14(1):153. doi: 10.1186/s12955-016-0557-9.
The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors.
This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant.
Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided.
The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.
本研究旨在评估土耳其慢性乙型肝炎（CHB）患者的健康相关生活质量（HRQOL）并研究相关因素。
这项多中心研究于2015年1月1日至4月15日在土耳其的57个中心进行。纳入成年人并分为三组进行研究。第1组：HBsAg携带者；第2组：接受抗病毒治疗的CHB患者；第3组：既未接受抗病毒治疗也不是HBsAg携带者的CHB患者。研究数据通过使用标准化问卷进行面对面访谈收集，问卷包括简明健康调查问卷（SF - 36）和乙型肝炎生活质量问卷（HBQOL）。分析中p < 0.05的值被认为具有统计学意义。
4257例CHB患者纳入本研究。其中2559例（60.1%）为男性。第1、2和3组分别由1529例（35.9%）、1721例（40.4%）和1007例（23.7%）患者组成。HRQOL最高值出现在HBsAg携带者中。我们发现使用抗病毒治疗时，总HBQOL评分会升高。然而，CHB患者的HRQOL因社会人口学特征而异。关于总HBQOL评分，在提供相关因素匹配对照时，非活动性HBV患者的HRQOL水平更高。
CHB患者的HRQOL评分高于预期，且疾病活动时可能恶化。使用抗病毒治疗有助于提高患者的HRQOL。
